Adaptimmune Quarterly report pursuant to Section 13 or 15(d)

Share-based compensation - Share-based Compensation Expense (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022
Total share-based compensation expense included in the consolidated statements of operations
Total share-based compensation expense	$ 3,837	$ 5,045	$ 5,513	$ 10,631
Research and development
Total share-based compensation expense included in the consolidated statements of operations
Total share-based compensation expense	1,285	2,033	1,401	4,556
General and administrative
Total share-based compensation expense included in the consolidated statements of operations
Total share-based compensation expense	$ 2,552	$ 3,012	$ 4,112	$ 6,075